Clover Health Investments, Corp. reports developments in physician enablement technology and Medicare Advantage insurance. The company offers PPO and HMO Medicare Advantage plans and uses its Clover Assistant software platform to aggregate patient data, support clinical decision-making, and address chronic disease management for Medicare populations.
Recurring Clover Health news includes quarterly and annual results, Medicare Advantage membership trends, medical cost and profitability metrics, and guidance updates. Company updates also cover Counterpart Health, the subsidiary that extends the data-driven physician enablement platform beyond Clover’s Medicare Advantage plan, including interoperability collaborations, patient data access, and clinical research tied to conditions such as diabetes, chronic kidney disease, congestive heart failure, COPD, and preventive care.
Clover Health (Nasdaq: CLOV) earned Best Medicare Advantage Plans recognition across three states in U.S. News & World Report’s 2027 ratings.
Its plans received the highest scores for Care Continuity in New Jersey, Georgia and South Carolina. In New Jersey, Clover also received Best Overall and Best for Screening & Prevention recognition. In Georgia, its plans earned the highest scores for Best Overall and tied for Best for Screening & Prevention. South Carolina plans received the highest scores in all three categories: Best Overall, Best for Screening & Prevention and Best for Care Continuity.
Clover Health (Nasdaq: CLOV) earned a 5-Star rating for its Medicare Advantage PPO plans for 2027, affecting payment year 2028. The Centers for Medicare & Medicaid Services (CMS) also awarded its HMO plan 4.5 Stars. The 5-Star rating enables year-round beneficiary enrollment in the PPO plans.
CMS calculated the PPO rating excluding 20 measures covered by a May 27, 2026 court decision that is on appeal. Including those measures would have produced 4.5 Stars. Clover’s score on core HEDIS measures, which assess care quality, remained 4.82 out of 5 Stars under either methodology.
Through the first half of 2026, Medicare Advantage membership grew ~48% year-over-year to more than 157,000 members, with ~98% in PPO plans. Clover said the higher rating allows further reinvestment in more competitive benefits.
Clover Health (Nasdaq: CLOV) will release its third-quarter 2026 financial results after the market closes on November 4, 2026.
Management will host a webcast at 5:00 p.m. Eastern Time that day to discuss quarterly business and financial performance. The live and archived webcast will be available through the company’s Investor Relations website, with the archive accessible for 12 months.
Clover Health (CLOV) announced its 2027 Medicare Advantage offerings, continuing its focus on preferred provider organization (PPO) plans and preventive care. The portfolio includes a commissionable $0-premium PPO, $0 in-network primary care copays and up to $400 in LiveHealthy Rewards for eligible healthy activities. Plans include routine dental, vision, over-the-counter and gym benefits.
The geographic footprint remains consistent with 2026, with plans available to 5.2 million Medicare-eligible beneficiaries across 203 counties in five states. New Jersey and Georgia remain core markets. The annual enrollment period runs from October 15 through December 7, 2026. Non-contracted providers are not obligated to treat members except in emergencies.
Clover Health (CLOV) appointed former U.S. Senator Robert Torricelli and physician Brian J. Miller to its board, effective September 24, 2026.
Torricelli will serve on the Audit Committee, and Miller will serve on the Clinical Committee. The appointments fill two previously disclosed vacancies and bring the board to nine directors. Torricelli represented New Jersey in Congress and has served on the boards of Clover’s insurance subsidiaries since 2022. Miller is a practicing hospitalist at Johns Hopkins Hospital and a commissioner on the Medicare Payment Advisory Commission, which advises Congress on Medicare payment policy.
Clover Health (CLOV) appointed former U.S. Senator Robert Torricelli and physician Brian J. Miller to its board, effective September 24, 2026.
Torricelli will serve on the Audit Committee, and Miller will serve on the Clinical Committee. The appointments fill two previously disclosed vacancies and bring the board to nine directors. Torricelli has served on the boards of Clover’s insurance subsidiaries since 2022. Miller is a commissioner on the Medicare Payment Advisory Commission and a practicing hospitalist at Johns Hopkins Hospital.
Clover Health (Nasdaq: CLOV) announced that Interim Chief Financial Officer Clay Thornton will participate in two upcoming investor events. He will present at the 2026 Jefferies Healthcare Services and Technology Conference on Tuesday, September 15, 2026, at 1:40 p.m. Eastern Time, with a live webcast and replay available on Clover Health's investor relations website.
Thornton will also participate in the Deutsche Bank 2026 Healthcare Summit on Wednesday, September 16, 2026. Clover Health describes itself as a physician enablement technology company focused on Medicare, leveraging its Clover Assistant platform and offering PPO and HMO Medicare Advantage plans, as well as extending its technology via its subsidiary Counterpart Health.
Clover Health (Nasdaq: CLOV) reported second quarter 2026 GAAP net income of $28 million, a $39 million improvement year-over-year, on total revenues of $743.2 million, up 55.6%. Consolidated Gross profit rose to $153.0 million, up 53.6%, and Adjusted EBITDA reached $40.9 million, up 139.2%.
Average Medicare Advantage membership increased to 156,840, up 48.7% year-over-year, with period-end insurance members of 157,309. Cash, cash equivalents and investments were $443.0 million, up 13.8% from 2025. Clover raised full-year 2026 guidance across revenues, Gross profit, Adjusted EBITDA, GAAP net income, and Medicare Advantage membership.
Clover Health (Nasdaq: CLOV) announced that Interim Chief Financial Officer Clay Thornton will present at the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, at 8:30 a.m. Eastern Time. A live webcast and replay of the presentation and Q&A will be available on Clover Health’s investor relations website.
Clover Health describes itself as a physician enablement technology company focused on Medicare, offering PPO and HMO Medicare Advantage plans and extending its Clover Assistant platform via its subsidiary Counterpart Health.
Clover Health (Nasdaq:CLOV) will report its second quarter 2026 financial results after market close on Wednesday, August 5, 2026. Management will host a webcast at 5:00 p.m. Eastern Time to discuss quarterly business and financial performance, with a live and archived stream available.